Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis
Authors
Yoon‐Ho Hong,
Vera BrilTuan Vu,
Chafic Karam,
Stojan Perić,
Francisco Garrido,
Hiroyuki Murai,
Andreas Meisel,
Said Beydoun,
Mamatha Pasnoor,
Antonio Segura,
Benjamin Hoorick,
Sophie Steeland,
Caroline T’joen,
Kimiaki Utsugisawa,
Jan Verschuuren,
Renato Mantegazza +15 authors
,
The Group Tip Tip